On February 6, 2024, Processa Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, announced that it has regained compliance with the NASDAQ's minimum closing bid price requirement, thereby maintaining its listing on the Nasdaq Capital Market. The company's stock had to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which it successfully achieved by February 2, 2024. This compliance follows NASDAQ Listing Rule 5550(a)(2), also known as the Minimum Bid Price Rule. The announcement was made through a press release and marks the closure of the matter with NASDAQ. Processa Pharmaceuticals specializes in developing next-generation chemotherapy drugs aimed at improving the efficacy and safety of cancer treatments. The company is currently working on three next-generation chemotherapy treatments targeting various cancers, including breast, colorectal, and pancreatic cancers.

On February 6, 2024, Processa Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, announced that it has regained compliance with the NASDAQ's minimum closing bid price requirement, thereby maintaining its listing on the Nasdaq Capital Market. The company's stock had to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which it successfully achieved by February 2, 2024. This compliance follows NASDAQ Listing Rule 5550(a)(2), also known as the Minimum Bid Price Rule. The announcement was made through a press release and marks the closure of the matter with NASDAQ. Processa Pharmaceuticals specializes in developing next-generation chemotherapy drugs aimed at improving the efficacy and safety of cancer treatments. The company is currently working on three next-generation chemotherapy treatments targeting various cancers, including breast, colorectal, and pancreatic cancers.